Últimas noticias sobre Prenetics Global (NASDAQ:PRE) Bolsa

PartnerRe

PartnerRe Ltd.

NYSE

Prenetics Global

Prenetics Global Ltd is a health sciences company, that is dedicated to consumer and clinical health. Its consumer initiative is led by IM8, a new health and wellness brand. The clinical division is led by Insighta, focused on multi-cancer early detection technologies. This is followed by ACT Genomics, which has achieved FDA clearance for genomic profiling of solid tumors, and CircleDNA, which uses NGS to offer DNA tests. Each Prenetics unit impacts health by 'enhancing life through science'.

Prenetics Global Limited - Class A Ordinary Share

Prenetics Global Ltd

Presearch

PRESTIGE CARS INTL by Prestige Cars International, Inc.

Prestige Cars International Inc

PREDICTIVE TECH GROUP INC by Predictive Technology Group, Inc.

Predictive Technology Group Inc

Principal Spectrum Preferred Securities Active ETF

PRECIPITATE GOLD CORP by Precipitate Gold Corp

Precipitate Gold Corp

PARTNERRE PFD SHS SER J by PartnerRe Ltd.

PartnerRe Ltd

PRAIRIESKY ROYALTY LTD by Prairiesky Royalty Ltd.

PrairieSky Royalty Ltd

PERPETUAL RES LTD ORD by Perpetual Resources Limited

Perpetual Resources Ltd

Pennsylvania Real Estate Investment Trust

Pennsylvania Real Estate Investment Trust 7 3/8 % Cum Red Perp Pfd Shs Series -B-

Pennsylvania Real Estate Investment Trust 7.20% Cum Red Perp Registered Pfd Shs Series -C-

Pennsylvania Real Estate Investment Trust 6.875% Cum Red Perp Pfd Shs Series -D-

Prosperity Real Estate Investment Trust

POWER RESOURCE EXPL INC by Power Resource Exploration Inc.

Power Resource Exploration Inc

<h3>Gainers</h3>
<ul>
<li>Prenetics Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRE#NASDAQ">PRE</a>) stock increased by 7.9% to $5.18 during Friday's after-market session. The market value of their outstanding shares is at $63.2 million. </li>
<li>Chromocell Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CHRO#AMEX">CHRO</a>) shares rose 5.39% to $0.67. The market value of their outstanding shares is at $3.8 million. </li>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) shares rose 5.3% to $1.39. The company's market cap stands at $2.5 million. </li>
<li>MiNK Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INKT#NASDAQ">INKT</a>) stock moved upwards by 4.99% to $0.75. The market value of their outstanding shares is at $29.6 million. </li>
<li>Accolade (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACCD#NASDAQ">ACCD</a>) shares rose 4.8% to $3.93. The market value of their outstanding shares is at $314.4 million. </li>
<li>Tharimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THAR#NASDAQ">THAR</a>) shares rose 4.76% to $2.2. The company's market cap stands at $2.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Trevena (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVN#NASDAQ">TRVN</a>) shares fell 42.5% to $2.65 during Friday's after-market session. The market value of their outstanding shares is at $2.2 million. </li>
<li>Entero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTO#NASDAQ">ENTO</a>) shares declined by 16.63% to $0.5. The market value of their outstanding shares is at $1.6 million. </li>
<li>NKGen Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKGN#NASDAQ">NKGN</a>) shares fell 14.25% to $0.34. The market value of their outstanding shares is at $12.1 million. </li>
<li>Kazia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KZIA#NASDAQ">KZIA</a>) shares fell 10.12% to $0.4. The market value of their outstanding shares is at $11.9 million. </li>
<li>Carmell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) shares declined by 9.63% to $0.36. The company's market cap stands at $7.4 million. </li>
<li>Silexion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) stock fell 6.77% to $0.43. The company's market cap stands at $4.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ACCD

CHRO

CTCX

ENTO

INKT

KZIA

NKGN

NUWE

SLXN

THAR

TRVN

12 Health Care Stocks Moving In Friday's After-Market Session

WIIM

Prenetics Global Limited shares are trading higher after the company announced the acquisition of Europa Sports Partners and its subsidiary, Hubmatrix.

News

Prenetics Global Acquires Europa Sports Partners And Hubmatrix To Accelerate Expansion Into U.S. Consumer Health And Wellness Market; Acquisition Supports IM8 Brand Co-Founded By David Beckham, Projecting Over $100M Revenue In FY2025

On Thursday, Prenetics Global Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRE#NASDAQ">PRE</a>) announced that former international footballer, entrepreneur, and philanthropist David Beckham has become a strategic investor in the business.
Prenetics and Beckham will become co-founding partners of a new health and wellness brand, IM8, which will <a target="_blank" href="https://www.sec.gov/Archives/edgar/data/1876431/000162828024031643/ex991.htm" rel="noreferrer noopener">focus</a> on consumer health products, with details to be announced at a later date.
Beckham said, &#8220;Throughout my life and career, I&#8217;ve been fortunate to have access to the best medical professionals, nutrition experts, and fitness coaches. Their guidance has been crucial to my health and well-being. That&#8217;s why I am excited to be working with Prenetics—a company dedicated to innovative, world-leading scientific advancements in health—as a co-founding partner and ambassador for IM8.&#8221;
Prenetics is a health sciences company. IM8, a new health and wellness brand, leads consumer initiatives.
The clinical division is led by Insighta, a $200 million joint venture with renowned scientist Prof. Dennis Lo, focused on multi-cancer early detection technologies.
Prenetics reported first-quarter revenue of $6.4 million, an increase of 30.2% compared <a target="_blank" href="https://www.benzinga.com/pressreleases/24/06/g39377509/prenetics-announces-first-quarter-2024-financial-results" rel="noreferrer noopener">to the first quarter of 2023</a>.
Danny Yeung, CEO and Co-Founder of Prenetics, remarked: &#8220;The first quarter of 2024 marked a good start for our company, showcasing solid growth in revenue and gross profit&#8230;Our purpose remains dedicated to our science-first approach in our pivot to consumer healthcare to broaden accessibility to science-based health and wellness.&#8221;
The company reported cash and other short-term assets&nbsp;of $86.6 million as of March 31, 2024.
Price Action: PRE shares are up 1.01% at $6.06 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/07/39726263/exclusive-vivani-medical-outlines-plans-to-kickstart-first-clinical-study-for-miniature-glp-1-obe" target="_blank" rel="noreferrer noopener">EXCLUSIVE: Vivani Medical Outlines Plans To Kickstart First Clinical Study For Miniature GLP-1 Obesity Implant Program This Year</a></li>
</ul>
Photo via Shutterstock

Health Care

Media

General

Renowned Footballer David Beckham Invests In Small Health & Wellness Firm Prenetics

Prenetics, (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRE#NASDAQ">PRE</a>) a leading health sciences company, is proud to&nbsp;announce&nbsp;that former international footballer, entrepreneur and philanthropist David Beckham has become a strategic investor in the business. Prenetics and Beckham will become co-founding partners of a new health and wellness brand, IM8, which will focus on cutting-edge consumer health products, with details to be announced at a later date.
Beckham said, "Throughout my life and career, I've been fortunate to have access to the best medical professionals, nutrition experts and fitness coaches. Their guidance has been crucial to my health and well-being. That's why I am excited to be working with Prenetics - a company that is dedicated to innovative, world-leading scientific advancements in health - as a co-founding partner and ambassador for IM8."

Prenetics Partners With David Beckham As Co-Found Partners For IM8, A New Health And Wellness Brand

Guidance

Prenetics Global Reaffirms 2024 Revenue Range Of $33M-$36M

Prenetics Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRE#NASDAQ">PRE</a>) reported quarterly losses of $(0.70) per share. This is a 44 percent increase over losses of $(1.25) per share from the same period last year. The company reported $6.41 million in sales this quarter. This is a 30.25 percent increase over sales of $4.92 million the same period last year.

Earnings

Prenetics Global Q1 EPS $(0.70) Up From $(1.25) YoY, Sales $6.41M Up From $4.92M YoY

<h3>Gainers</h3>
<ul>
<li>GeneDx Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>) shares increased by 21.8% to $13.4 during Monday's after-market session. The market value of their outstanding shares is at $349.1 million. The company's, Q1 earnings came out today. </li>
<li>InnovAge Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INNV#NASDAQ">INNV</a>) shares increased by 7.25% to $3.99. The market value of their outstanding shares is at $542.2 million. </li>
<li>Mustang Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIO#NASDAQ">MBIO</a>) shares increased by 5.48% to $0.25. The market value of their outstanding shares is at $2.5 million. </li>
<li>Lucid Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCD#NASDAQ">LUCD</a>) stock moved upwards by 5.23% to $0.79. The market value of their outstanding shares is at $38.1 million. </li>
<li>Seelos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEEL#NASDAQ">SEEL</a>) shares increased by 4.88% to $0.29. The market value of their outstanding shares is at $4.0 million. </li>
<li>NewAmsterdam Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAMS#NASDAQ">NAMS</a>) shares increased by 4.8% to $22.7. The market value of their outstanding shares is at $2.0 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) stock declined by 10.7% to $0.5 during Monday's after-market session. The market value of their outstanding shares is at $13.3 million. </li>
<li>Vaxxinity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VAXX#NASDAQ">VAXX</a>) stock decreased by 9.44% to $0.14. The company's market cap stands at $18.1 million. </li>
<li>Ekso Bionics Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EKSO#NASDAQ">EKSO</a>) stock fell 5.43% to $1.22. The market value of their outstanding shares is at $21.8 million. As per the press release, Q1 earnings came out today. </li>
<li>Cosmos Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COSM#NASDAQ">COSM</a>) shares declined by 5.0% to $0.67. The company's market cap stands at $11.3 million. </li>
<li>Inozyme Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INZY#NASDAQ">INZY</a>) stock decreased by 4.98% to $4.2. The market value of their outstanding shares is at $259.4 million. </li>
<li>Prenetics Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRE#NASDAQ">PRE</a>) shares fell 4.73% to $4.24. The market value of their outstanding shares is at $51.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

COSM

EKSO

GCTK

INNV

INZY

LUCD

MBIO

NAMS

SEEL

VAXX

12 Health Care Stocks Moving In Monday's After-Market Session

Shares of Teledyne Technologies Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDY#NYSE">TDY</a>) fell sharply during Wednesday's session after the company reported worse-than-expected first-quarter financial results and <a href="https://www.benzinga.com/quote/TDY/earnings">cut FY24 adjusted EPS guidance.</a>
Teledyne Technologies posted adjusted earnings of $4.55 per share, missing market estimates of $4.63 per share. The company's quarterly sales came in at $1.35 billion versus expectations of $1.40 billion, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Teledyne Technologies shares dipped 9.3% to $369.16 on Wednesday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Chicken Soup for the Soul Entertainment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSSE#NASDAQ">CSSE</a>) gained 136% to $0.3570.</li>
<li>BranchOut Food Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOF#NASDAQ">BOF</a>) shares climbed 73% to $1.98 after the company announced it has expanded its existing relationship with the nation&#8217;s largest retailer, which brings the total annualized value of commitments from the retailer to over $8 million.</li>
<li>Amesite Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMST#NASDAQ">AMST</a>) jumped 55.7% to $3.10 after the company announced the Beta release of its NurseMagic app.</li>
<li>Lichen China Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LICN#NASDAQ">LICN</a>) gained 53.5% to $0.8599.</li>
<li>WiMi Hologram Cloud Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WIMI#NASDAQ">WIMI</a>) rose 44.6% to $1.05.</li>
<li>Mullen Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>) rose 44% to $3.93.</li>
<li>Prenetics Global Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRE#NASDAQ">PRE</a>) gained 36.6% to $6.25.</li>
<li>B. Riley Financial, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RILY#NASDAQ">RILY</a>) shares surged 29.9% to $28.20 after the company announced the results of an independent investigation showed the company and its executives had no involvement with, or knowledge of, any of the alleged misconduct concerning Mr. Kahn or any of his affiliates.</li>
<li>MMTec, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTC#NASDAQ">MTC</a>) shares climbed 29% to $2.8948.</li>
<li>Connexa Sports Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YYAI#NASDAQ">YYAI</a>) gained 28.8% to $0.9427.</li>
<li>Ribbon Communications Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBBN#NASDAQ">RBBN</a>) shares rose 27.2% to $3.2699 after the company reported first-quarter financial results and issued guidance.</li>
<li>TROOPS, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TROO#NASDAQ">TROO</a>) gained 26.6% to $1.38.</li>
<li>Babcock &amp; Wilcox Enterprises, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BW#NYSE">BW</a>) gained 19.9% to $1.10</li>
<li>Hasbro, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAS#NASDAQ">HAS</a>) surged 12.1% to $65.13 following better-than-expected first-quarter financial results.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) gained 11.9% to $161.93 following first-quarter results.</li>
<li>Vertiv Holdings Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>) climbed 11.2% to $88.07 after the company reported better-than-expected first-quarter financial results and raised its 2024 guidance.</li>
<li>Intchains Group Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ICG#NYSE">ICG</a>) gained 10.3% to $10.30.</li>
<li>Navitas Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>) surged 9.2% to $4.1402. Navitas Semiconductor is expected to report first-quarter financial results on Thursday, May 9.</li>
<li>Westinghouse Air Brake Technologies Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAB#NYSE">WAB</a>) surged 9% to $161.84 after the company reported better-than-expected first-quarter financial results and raised its 2024 guidance.</li>
<li>Stride, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LRN#NYSE">LRN</a>) surged 8.4% to $63.07 after the company reported better-than-expected third-quarter financial results and issued FY24 revenue guidance above estimates.</li>
<li>Texas Instruments Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>) gained 6.4% to $176.10 following a first-quarter earnings beat.</li>
<li>Boston Scientific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) surged 6.2% to $73.24 after the company reported better than expected first-quarter earnings and issued guidance.</li>
<li>Hilton Worldwide Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLT#NYSE">HLT</a>) rose gained 4.4% to $205.69 after the company reported better-than-expected first-quarter financial results and raised FY24 adjusted EPS guidance.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Neo-Concept International Group Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCI#NASDAQ">NCI</a>) fell 67.4% to $3.06 after jumping over 137% on Tuesday. The company priced its IPO at $4 per share.</li>
<li>iSun, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISUN#NASDAQ">ISUN</a>) fell 40% to $0.0901 after the company announced a reverse stock split.</li>
<li>GlucoTrack, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) declined 36.8% to $0.4801.</li>
<li>Evotec SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) shares dipped 32.4% to $5.27 after reporting fiscal year 2023 results.</li>
<li>Avenue Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXI#NASDAQ">ATXI</a>) fell 31% to $0.0925 after the company announced a reverse stock split.</li>
<li>Vaxxinity, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VAXX#NASDAQ">VAXX</a>) dipped 26.8% to $0.1464.</li>
<li>Applied DNA Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) fell 20% to $0.2320.</li>
<li>Brand Engagement Network, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNAI#NASDAQ">BNAI</a>) shares dipped 19.5% to $3.46.</li>
<li>NewGenIvf Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares declined 18.8% to $1.81.</li>
<li>Recon Technology, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCON#NASDAQ">RCON</a>) fell 16.5% to $0.0845.</li>
<li>Finch Therapeutics Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FNCH#NASDAQ">FNCH</a>) fell 15.5% to $2.35.</li>
<li>New Oriental Education &amp; Technology Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EDU#NYSE">EDU</a>) shares slipped 13.9% to $77.13 following downbeat quarterly earnings.</li>
<li>Mersana Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRSN#NASDAQ">MRSN</a>) fell 11% to $2.8600.</li>
<li>Helen of Troy Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HELE#NASDAQ">HELE</a>) dipped 9.8% to $90.45 after the company reported fourth-quarter financial results and issued FY25 guidance below estimates.</li>
<li>Old Dominion Freight Line, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODFL#NASDAQ">ODFL</a>) shares declined 9.7% to $197.95 following a first-quarter revenue miss.</li>
<li>Vicor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VICR#NASDAQ">VICR</a>) dipped 8.5% to $32.17 after the company reported worse-than-expected first-quarter sales results.</li>
<li>Sleep Number Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNBR#NASDAQ">SNBR</a>) fell 8.4% to $13.38.</li>
<li>Manhattan Associates, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MANH#NASDAQ">MANH</a>) shares declined 8.4% to $211.18 following quarterly results.</li>
<li>Equinox Gold Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQX#NYSE">EQX</a>) fell 8.2% to $5.25. Equinox Gold entered into a binding share purchase agreement with certain funds managed by Orion Mine Finance Management LP to acquire Orion&#8217;s 40% interest in Greenstone Gold Mine GP Inc., giving Equinox Gold 100% ownership of the Greenstone Mine in Ontario, Canada.</li>
<li>Enphase Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) fell 4.5% to $108.43 after the company reported worse-than-expected first-quarter financial results and issued second-quarter revenue guidance below estimates.</li>
<li>Lithia Motors, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAD#NYSE">LAD</a>) shares fell 4.3% to $253.02 following downbeat quarterly earnings.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/24/04/38400974/tesla-to-180-here-are-10-top-analyst-forecasts-for-wednesday">Tesla To $180? Here Are 10 Top Analyst Forecasts For Wednesday</a>

AMST

APDN

ATXI

BNAI

CSSE

New Oriental Education & Technology Group

ENPH

FNCH

HELE

ISUN

LICN

MANH

MRSN

MULN

NIVF

NVTS

ODFL

RBBN

RCON

RILY

SNBR

TROO

TSLA

VICR

WIMI

Connexa Sports Technologies Inc. - Common Stock

YYAI

Why Teledyne Technologies Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

<h3>Gainers</h3>
<ul>
<li>Catheter Precision (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#AMEX">VTAK</a>) shares moved upwards by 27.8% to $0.58 during Wednesday's regular session. The company's market cap stands at $4.4 million. </li>
<li>Prenetics Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRE#NASDAQ">PRE</a>) stock moved upwards by 26.25% to $5.77. The company's market cap stands at $70.4 million. </li>
<li>Alterity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHE#NASDAQ">ATHE</a>) stock rose 15.02% to $2.45. The market value of their outstanding shares is at $21.3 million. </li>
<li>Immutep (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMMP#NASDAQ">IMMP</a>) shares increased by 13.54% to $2.85. The market value of their outstanding shares is at $338.8 million. </li>
<li>CareMax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMAX#NASDAQ">CMAX</a>) shares rose 12.89% to $3.94. The market value of their outstanding shares is at $14.9 million. </li>
<li>SINTX Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) stock moved upwards by 12.84% to $0.04. The market value of their outstanding shares is at $4.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) shares decreased by 38.2% to $0.47 during Wednesday's regular session. The company's market cap stands at $12.5 million. </li>
<li>Evotec (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) shares decreased by 31.9% to $5.21. The market value of their outstanding shares is at $1.8 billion. As per the news, the Q4 earnings report came out today. </li>
<li>Vaxxinity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VAXX#NASDAQ">VAXX</a>) stock fell 26.51% to $0.15. The market value of their outstanding shares is at $18.6 million. </li>
<li>Addex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADXN#NASDAQ">ADXN</a>) shares fell 18.9% to $15.2. The market value of their outstanding shares is at $16.2 million. As per the news, the Q4 earnings report came out 4 days ago. </li>
<li>Kiora Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPRX#NASDAQ">KPRX</a>) stock declined by 15.41% to $0.49. The market value of their outstanding shares is at $12.8 million. </li>
<li>Sunshine Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) shares decreased by 14.87% to $1.03. The market value of their outstanding shares is at $1.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADXN

Alterity Therapeutics Limited - American Depositary Shares

ATHE

CMAX

IMMP

Kiora Pharmaceuticals, Inc. - Common Stock

KPRX

SBFM

SINT

VTAK

12 Health Care Stocks Moving In Wednesday's Intraday Session

Cantor Fitzgerald analyst Ross Osborn maintains Prenetics Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRE#NASDAQ">PRE</a>) with a Overweight and lowers the price target from $10 to $9.

Price Target

Analyst Ratings

Cantor Fitzgerald Maintains Overweight on Prenetics Global, Lowers Price Target to $9

Prenetics Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRE#NASDAQ">PRE</a>) reported its Q4 earnings results on Monday, April 1, 2024 at 07:30 AM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Prenetics Global beat estimated earnings by 32.0%, reporting an EPS of $-0.51 versus an estimate of $-0.75.
Revenue was down $46.89 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company missed on EPS by $0.0 which was followed by a 0.0% increase in the share price the next day.
Here's a look at Prenetics Global's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.05</td>
<td>-0.75</td>
<td>0.9</td>
<td>-1.5</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.05</td>
<td>-0.75</td>
<td>-0.6</td>
<td>0.9</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>18.14M</td>
<td>25.98M</td>
<td>24.20M</td>
<td>54.97M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>4.87M</td>
<td>5.70M</td>
<td>17.70M</td>
<td>52.32M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Prenetics Global <a href="https://www.benzinga.com/quote/PRE/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Prenetics Global: Q4 Earnings Insights

Prenetics Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRE#NASDAQ">PRE</a>) reported quarterly losses of $(0.51) per share which beat the analyst consensus estimate of $(0.75) by 32 percent. This is a 139.23 percent decrease over earnings of $1.30 per share from the same period last year. The company reported quarterly sales of $5.43 million which missed the analyst consensus estimate of $17.60 million by 69.16 percent. This is a 90.84 percent increase over sales of $2.84 million the same period last year.

Prenetics Global Q4 Adjusted EPS $(0.51) Beats $(0.75) Estimate, Sales $5.43M May Not Be Comparable To $17.60M Estimate

<h3>Gainers</h3>
<ul>
<li>Stoke Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STOK#NASDAQ">STOK</a>) stock moved upwards by 71.8% to $11.16 during Tuesday's regular session. The company's market cap stands at $498.5 million. The company's, Q4 earnings came out yesterday. </li>
<li>Mesoblast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) stock moved upwards by 64.95% to $3.63. The market value of their outstanding shares is at $368.2 million. </li>
<li>OpGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPGN#NASDAQ">OPGN</a>) shares increased by 42.1% to $0.68. The company's market cap stands at $6.7 million. </li>
<li>Alpha Teknova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TKNO#NASDAQ">TKNO</a>) shares rose 36.92% to $3.3. The market value of their outstanding shares is at $134.6 million. </li>
<li>Nuvation Bio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUVB#NYSE">NUVB</a>) shares moved upwards by 32.22% to $2.98. The company's market cap stands at $651.6 million. </li>
<li>Journey Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>) stock moved upwards by 28.42% to $3.75. The company's market cap stands at $72.4 million. As per the press release, Q4 earnings came out 3 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>NeuBase Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBSE#NASDAQ">NBSE</a>) stock declined by 51.8% to $0.48 during Tuesday's regular session. The company's market cap stands at $1.7 million. </li>
<li>Prenetics Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRE#NASDAQ">PRE</a>) shares decreased by 18.23% to $3.68. The company's market cap stands at $44.9 million. </li>
<li>Equillium (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQ#NASDAQ">EQ</a>) stock decreased by 18.04% to $2.0. The market value of their outstanding shares is at $70.2 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>SCWorx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) shares fell 17.11% to $2.81. The company's market cap stands at $3.4 million. </li>
<li>Monte Rosa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLUE#NASDAQ">GLUE</a>) stock decreased by 17.03% to $7.02. The company's market cap stands at $352.0 million. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares decreased by 15.37% to $0.83. The company's market cap stands at $3.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BDRX

DERM

GLUE

MESO

NBSE

NUVB

OPGN

STOK

TKNO

WORX

12 Health Care Stocks Moving In Tuesday's Intraday Session

<ul>
<li>Initial research project is with NDORMS, Botnar Research Institute, University of Oxford, focusing on accelerated aging in space</li>
<li>Dr. James L. Green, former Chief Scientist of NASA and Dr. Tara Ruttley, former Associate Chief Scientist of NASA to join Prenetics Scientific Advisory Board</li>
<li>Inaugural research cube scheduled to be sent on-board SpaceX to the ISS in Q4 of 2024 &nbsp;</li>
</ul>
DUBAI, United Arab Emirates, Feb. 09, 2024 (GLOBE NEWSWIRE) -- UAE Space Agency&nbsp;– Prenetics Global Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRE#NASDAQ">PRE</a>), a leading genomics-driven health sciences company, announces the signing of a Memorandum of Understanding (MOU), that paves the way for a strategic investment in Metavisionaries and a pioneering five-year research agreement with them and their partners Space Application Services through their Metaspace Venture. The parties will also establish a Space Innovation Lab within the UAE Space Agency. The inaugural Prenetics research cube is scheduled to on-board the SpaceX to the ISS in Q4 of 2024.
Mohsen Al Alwadi, Director of the Space Missions Department at the UAE Space Agency remarked: "The UAE Space Agency is thrilled to support the initiative of the Prenetics and Metavisionaries partnership, in building the space ecosystem by engaging non-space industry partners in innovation, space exploration and in human health."
As space exploration ignites a new era of discovery, the first endeavor by Prenetics will be with the Botnar Institute for Musculoskeletal Sciences at the University of Oxford, NDORMS, led by Dr. Ghada Alsaleh. The joint project will be to research cellular solutions that promote rejuvenation and vitality to combat the phenomenon of accelerated aging in space due to its zero-gravity environment. The potential of this research could lead to new advances in healthcare, enhancing cellular health and longevity for all ages on Earth.
Danny Yeung, CEO of Prenetics stated: "Our collaboration with Metavisionaries underscores our dedication to innovation and our conviction in the transformative potential of space exploration to deliver ground-breaking health advancements on Earth."
Ahmed Alfandi, President of Metavisionaries, said "Joining forces with Prenetics will lay the groundwork for monumental scientific advancements that have the potential to benefit all of humanity."
Prenetics is also proud to announce that Dr. James L. Green, Chairman of Metavisionaries and former Chief Scientist of NASA, alongside Dr. Tara Ruttley, Director of Sciences of Metavisionaries and former Associate&nbsp;Chief&nbsp;Scientist of NASA, will join the Prenetics Scientific Advisory Board. Concurrently, Danny Yeung, CEO of Prenetics will join the Board of Directors at Metavisionaries, fortifying its strategic vision. &nbsp;
"In my 42+ years at NASA, I've witnessed space research develop remarkable medical technologies which power CAT scanners, MRI, portable ECG machines, which have had significant medical and commercial success. I'm excited to contribute to Prenetics' mission and to translate space research into health innovations on Earth," said Dr. James L. Green.

Global

Prenetics Announces MOU For A Strategic Investment And 5-Year Research Collaboration With Metavisionaries To Pioneer R&D On The International Space Station

<h3>Understanding Value Stocks</h3>
A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be undervalued, as investors are not expressing as much interest in such companies. The most commonly used way to check for value is with the price-to-earnings multiple, or P/E. A low P/E multiple is a good indication that the stock is undervalued. 
<h2>Below is a list of notable value stocks in the healthcare sector:</h2>
<ol>
<li>Cross Country Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCRN#NASDAQ">CCRN</a>) - P/E: 7.31</li>
<li>Prenetics Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRE#NASDAQ">PRE</a>) - P/E: 1.0</li>
<li>Spero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) - P/E: 3.0</li>
<li>Arcturus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>) - P/E: 6.62</li>
<li>Zymeworks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYME#NASDAQ">ZYME</a>) - P/E: 2.83</li>
</ol>
This quarter, Cross Country Healthcare experienced a decrease in earnings per share, which was $0.69 in Q2 and is now $0.39. Prenetics Global saw an increase in earnings per share from -0.75 in Q2 to $-0.05 now. Its most recent dividend yield is at 1.99%, which has decreased by 0.02% from 2.01% in the previous quarter.
Spero Therapeutics saw an increase in earnings per share from -0.23 in Q2 to $-0.06 now. Most recently, Arcturus Therapeutics reported earnings per share at $-0.61, whereas in Q2 earnings per share sat at $-1.98. Most recently, Zymeworks reported earnings per share at $-0.38, whereas in Q2 earnings per share sat at $-0.75. 
The Significance: A value stock may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize.

ARCT

CCRN

SPRO

ZYME

5 Value Stocks In The Healthcare Sector

<h3>Understanding Value Stocks</h3>
A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock. 
<h2>The following stocks are considered to be notable value stocks in the healthcare sector:</h2>
<ol>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) - P/E: 0.02</li>
<li>Exicure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) - P/E: 0.33</li>
<li>Acorda Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACOR#NASDAQ">ACOR</a>) - P/E: 3.69</li>
<li>Prenetics Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRE#NASDAQ">PRE</a>) - P/E: 0.24</li>
<li>Ocuphire Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUP#NASDAQ">OCUP</a>) - P/E: 2.03</li>
</ol>
Most recently, Nuwellis reported earnings per share at $-1.81, whereas in Q2 earnings per share sat at $-3.65. Exicure has reported Q2 earnings per share at $-0.68, which has increased by 2.86% compared to Q1, which was -0.7. Acorda Therapeutics's earnings per share for Q3 sits at $-7.16, whereas in Q2, they were at -7.55. Prenetics Global looks to be undervalued. It possesses an EPS of $-0.05, which has not changed since last quarter (Q2). Most recently, the company reported a dividend yield of 1.99%, which has decreased by 0.02% from last quarter's yield of 2.01%.
Ocuphire Pharma saw an increase in earnings per share from -0.24 in Q2 to $0.25 now. 
The Significance: A value stock may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize.

ACOR

OCUP

XCUR

A Look Into Healthcare Sector Value Stocks

Prenetics Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRE#NASDAQ">PRE</a>) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.06) by 16.67 percent. This is a 116.67 percent decrease over earnings of $0.30 per share from the same period last year. The company reported quarterly sales of $4.87 million which missed the analyst consensus estimate of $18.14 million by 73.18 percent. This is a 13.29 percent increase over sales of $4.30 million the same period last year.

Prenetics Global Q3 EPS $(0.05) Beats $(0.06) Estimate, Sales $4.87M May Not Be Comparable To $18.14M Estimate

Prenetics Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRE#NASDAQ">PRE</a>) reported its Q3 earnings results on Monday, November 20, 2023 at 08:00 AM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Prenetics Global reported in-line EPS of $-0.05 versus an estimate of $-0.05.
Revenue was down $74.81 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company missed on EPS by $0.0 which was followed by a 2.06% drop in the share price the next day.
Here's a look at Prenetics Global's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
<th>Q3 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.05</td>
<td>-0.06</td>
<td>-0.10</td>
<td>-0.04</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.05</td>
<td>-0.04</td>
<td>0.06</td>
<td>0.30</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>25.98M</td>
<td>24.20M</td>
<td>54.97M</td>
<td>66.58M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>5.70M</td>
<td>17.70M</td>
<td>52.32M</td>
<td>79.68M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Prenetics Global <a href="https://www.benzinga.com/quote/PRE/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Prenetics Global: Q3 Earnings Insights

StoneCo Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/stne#NASDAQ">STNE</a>) shares rose in pre-market trading after the company reported upbeat results for its third quarter on Friday.
StoneCo posted adjusted earnings of 27 cents per share, beating market estimates of 22 cents per share. The company&rsquo;s sales came in at $643.35 million versus expectations of $610.17 million.
StoneCo shares gained 6.3% to $11.40 in pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3>Gainers</h3>
<ul>
<li>SenesTech, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/snes#NASDAQ">SNES</a>) shares rose 81.3% to $0.4341 in pre-market trading. SenesTech shares fell 31% on Friday after the company reported worse-than-expected third-quarter revenue results.</li>
<li>Collective Audience, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/caud#NASDAQ">CAUD</a>) shares surged 57.2% to $4.67 in pre-market trading after jumping around 30% on Friday.</li>
<li>Tivic Health Systems, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tivc#NASDAQ">TIVC</a>) shares rose 26.7% to $1.52 in pre-market trading. -Tivic Health Systems is expected to report financial results for the third quarter 2023 on Nov. 14, 2023.</li>
<li>Cazoo Group Ltd (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/czoo#NYSE">CZOO</a>) shares climbed 21.4% to $0.4250 in pre-market trading after falling 11% on Friday.</li>
<li>Near Intelligence, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nir#NASDAQ">NIR</a>) shares rose 21.1% to $0.23 in pre-market trading after dipping 31% on Friday.</li>
<li>LQR House Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lqr#NASDAQ">LQR</a>) rose 17% to $0.1053 in pre-market trading after gaining around 8% on Friday. The company announced the pricing of a $11 million public offering of 157,142,857 shares at $0.07 per share.</li>
<li>Dogness (International) Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dogz#NASDAQ">DOGZ</a>) rose 16.6% to $3.79 in pre-market trading.</li>
<li>reAlpha Tech Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aire#NASDAQ">AIRE</a>) shares rose 16.1% to $5.11 in pre-market trading after falling 11% on Friday.</li>
<li>Prenetics Global Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pre#NASDAQ">PRE</a>) gained 12% to $0.3897 in pre-market trading after gaining around 5% on Friday.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Monopar Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mnpr#NASDAQ">MNPR</a>) dipped 23.7% to $0.29 in pre-market trading after falling over 8% on Friday. Monopar Therapeutics, last week, posted a narrower-than-expected quarterly loss.</li>
<li>eFFECTOR Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eftr#NASDAQ">EFTR</a>) shares fell 17% to $0.4898 in pre-market trading.</li>
<li>Motus GI Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mots#NASDAQ">MOTS</a>) shares fell 15.4% to $3.37 in pre-market trading. Motus GI shares gained around 13% on Friday after the company announced the Pure-Vu EVS Gastro was successfully used in the first procedure since receiving FDA clearance.</li>
<li>Safe and Green Development Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sgd#NASDAQ">SGD</a>) shares fell 14.3% to $0.5999 in pre-market trading after jumping 36% on Friday.</li>
<li>Verve Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/verv#NASDAQ">VERV</a>) shares fell 14.1% to $13.50 in pre-market trading after the company announced first human proof-of-concept data for in vivo base editing from the ongoing heart-1 phase 1b clinical trial of VERVE-101.</li>
<li>Kodiak Sciences Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kod#NASDAQ">KOD</a>) shares fell 14% to $1.48 in pre-market trading after declining 6% on Friday. Kodiak Sciences recently said its Phase 3 GLOW superiority study evaluating tarcocimab tedromer 5 mg in moderately severe to severe NPDR met its one-year primary endpoint.</li>
<li>GlucoTrack, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gctk#NASDAQ">GCTK</a>) shares fell 12.9% to $0.1376 in pre-market trading.</li>
<li>Intelligent Bio Solutions Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/inbs#NASDAQ">INBS</a>) fell 12.6% to $0.5044 in pre-market trading after surging around 32% on Friday.</li>
<li>Intrusion Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/intz#NASDAQ">INTZ</a>) fell 12.3% to $0.42 in pre-market. The company announced that it entered into a Securities Purchase Agreement through a $2.4 million Private Offering of 4,359,374 shares at $0.60 per share.</li>
<li>TRACON Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tcon#NASDAQ">TCON</a>) fell 9.9% to $0.2075 in pre-market trading. TRACON Pharmaceuticals shares jumped 44% on Friday after the company reported third-quarter financial results.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/23/11/35724724/over-13m-bet-on-this-energy-stock-check-out-these-4-stocks-insiders-are-buying"> Over $13M Bet On This Energy Stock? Check Out These 4 Stocks Insiders Are Buying</a>

Penny Stocks

Small Cap

Pre-Market Outlook

Markets

Trading Ideas

AIRE

CAUD

CZOO

DOGZ

EFTR

Intelligent Bio Solutions Inc. - Common Stock

INBS

INTZ

MNPR

MOTS

SNES

STNE

TCON

TIVC

VERV

Why StoneCo Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket

Prenetics Group Limited (PRE) has disclosed a new risk, in the Technology category. Prenetics Group Limited faces a substantial business risk with ...

ERP Rollout Risks at Prenetics: Navigating Potential Pitfalls in Financial Operations Overhaul

Prenetics Group (PRE) has released an update. Prenetics Group has reported a strong start to 2024 with a 30.2% increase in first-quarter revenue an...

Prenetics Group Reports Solid Q1 Growth

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Prenetics Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/pre-stock-quote/">PRE</a>) just reported results for the first quarter of 2024.<ul><li>Prenetics Global reported earnings per share of -38 cents.</li><li>The company reported revenue of $6.41 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/06/pre-stock-earnings-prenetics-global-for-q1-of-2024/">PRE Stock Earnings: Prenetics Global Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

PRE Stock Earnings: Prenetics Global Reported Results for Q1 2024

Prenetics Global GAAP EPS of -$0.70 beats by $0.32, revenue of $6.4M beats by $0.2M

Prenetics Group (PRE) has released an update. Prenetics Group has entered into a Subscription Agreement for the issuance of Class A Ordinary Shares...

Prenetics Group Announces New Share Subscription

Prenetics Group (PRE) has released an update. Prenetics Group has strategically acquired Europa Sports Partners, significantly expanding its reach ...

Prenetics Acquires Europa, Eyes Wellness Market Growth

Earnings week ahead: Adobe, Oracle, Kroger, GameStop and more

Prenetics Group (PRE) has released an update. Prenetics Global Limited, a key player in the health technology sector, has officially announced its ...

Prenetics Group Dismisses KPMG Amid Financial Strategy Shift

Earnings week ahead: Micron, Costco, BlackBerry, Accenture and more

Prenetics Group (PRE) has released an update. Prenetics Global Limited has received consent from its independent auditor, Plante & Moran, PLLC, for...

Comments

Prenetics Global

Noticias

Últimas noticias sobre Prenetics Global (NASDAQ:PRE) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL